SA
IDXX icon

Strategic Advocates’s Idexx Laboratories IDXX Stock Holding History

Strategic Advocates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.8K Buy
69
+61
+763% +$39.1K 0.17% 91
2025
Q4 		$5.46K Hold
8
– – ﹤0.01% 421
2025
Q3 		$5.11K Buy
+8
New +$4.86K ﹤0.01% 406

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Strategic Advocates's IDXX Position: Q1 2026 in Review

Strategic Advocates increased its Idexx Laboratories (IDXX) stake by 763% in Q1 2026, buying an estimated $39.1K and bringing the position to 69 shares worth $38.8K. The position accounts for 0.17% of the portfolio, ranked #91.

Strategic Advocates first reported a position in IDXX in Q3 2025 and has held it in 3 quarters since. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Strategic Advocates held 69 shares of Idexx Laboratories worth $38.8K as of Q1 2026.
  • Strategic Advocates bought 61 Idexx Laboratories shares in Q1 2026, an estimated $39.1K.
  • Idexx Laboratories made up 0.17% of Strategic Advocates's portfolio in Q1 2026, its #91 holding.
  • Strategic Advocates first reported a position in Idexx Laboratories in Q3 2025 and has held it in 3 quarters since.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.